The association of megalin and cubilin genetic variants with serum levels of 25-hydroxvitamin D and the incidence of acute coronary syndrome in Egyptians: A case control study

Raghda A. Elsabbagh a, Mohamed F. Abdel Rahman b, Sally I. Hassanein a, Rasha S. Hanafi c, Reem A. Assal d, Gamal M. Shaban e, Mohamed Z. Gad a,⇑

aClinical Biochemistry Unit, Faculty of Pharmacy and Biotechnology, The German University in Cairo, Egypt
bBiochemistry Department, Faculty of Pharmacy, October University for Modern Science and Arts, 6th of October City, Egypt
cDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, The German University in Cairo, Egypt
dDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, The German University in Cairo, Egypt
eNational Heart Institute, Cairo, Egypt

HIGHLIGHTS

• The manuscript describes the link of vitamin D deficiency to acute coronary syndrome.
• It tackles megalin and cubilin genetic variants in ACS Egyptians.
• It explores the effects of megalin and cubilin polymorphisms on serum 25(OH)D levels.
• Megalin rs4668123 (CC) can be considered an independent risk factor for ACS incidence.
• Megalin rs4668123 (CC) was linked to lower 25(OH)D levels.

ABSTRACT

Megalin and cubilin are two receptors that mediate endocytosis of 25-hydroxyvitamin D (25(OH)D) for its final activation by hydroxylation. The aim of the present study was to evaluate the association of polymorphisms in megalin (rs2075252 and rs4668123) and cubilin (rs1801222 and rs12766939) with the circulating serum levels of 25(OH)D and with the early incidence of acute coronary syndrome (ACS) in Egyptians. The study included 328 subjects; 185 ACS patients aged between 27 and 60 years, and 143 healthy age-matched controls. Genotyping of cubilin rs12766939 Single Nucleotide Polymorphism (SNP) was performed using Real-Time Polymerase Chain Reaction (qPCR) and for megalin rs4668123 and rs2075252 and cubilin rs1801222 by Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP). 25(OH)D levels were measured by Ultra Performance Liquid Chromatography- Tandem Mass Spectroscopy (UPLC-MS/MS). Results showed that vitamin D deficiency
was highly linked to ACS incidence (P < 0.0001). The megalin rs4668123 CC, cubulin rs1801222 GG and cubulin rs12766939 GG + GA genotypes are associated with a higher ACS incidence and can be considered risk factors, according to Chi-squared test (P = 0.0003, 0.0442, 0.013 respectively). Conversely, the megalin rs2075252 SNP was not associated with increased ACS incidence. However, after performing multiple logistic regression analysis, only the megalin rs4668123 SNP was considered an independent ACS risk factor. Furthermore, the megalin rs4668123 CC genotype was associated with lower 25(OH)D levels (P = 0.0018). In conclusion, megalin rs4668123 (CC) was linked to lower 25(OH)D levels and can be considered an independent risk factor for incidence of ACS.

© 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Due to a series of revolutionary discoveries in the last decade, vitamin D has stepped out from the shadows of bone diseases to emerge as a prominent player in non-calcemic actions. Vitamin D exists in two forms, D2 and D3, where D3 is the principal form in humans, photosynthesized from 7-dehydrocholesterol precursor in the epidermal and dermal cells [1]. Vitamin D is biologically inert and must undergo two activation phases: 25-hydroxylation in the liver and 1α-hydroxylation in the kidney [2,3]. These steps yield the biologically active form, 1,25-dihydroxyvitamin D (1,25(OH)2D) [4].

Unfortunately, almost 1 billion people worldwide, across all ethnicities and age groups, are vitamin D deficient and nearly 50% are vitamin D insufficient [5]. Paradoxically, although the Middle East receives abundant sunshine throughout the year, one third to one half of its inhabitants have deficient serum levels of 25-hydroxyvitamin D (25(OH)D) [6]. Numerous studies have linked vitamin D deficiency with insidious long-term consequences that can imprint on children and adults for the rest of their lives, such as increased risk for type 1 diabetes, multiple sclerosis, cancers and cardiovascular diseases (CVDs) [3]. Cardiovascular disease is recognized as the leading cause of death and disability worldwide accounting for 30% of all global deaths per year [7]. Among all CVDs, acute coronary syndrome (ACS) is the number one killer in both genders, accounting for 46% of cardiovascular deaths among men and 38% among women [8]. ACS is the umbrella term for the clinical signs and symptoms of: unstable angina together with myocardial infarction, including non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI) [9].

It would be of value to mention the positive influence of vitamin D with relevance to the cardiovascular system. Vitamin D induces vascular endothelial growth factor production, thus promoting endothelial repair. Vitamin D also protects against atherosclerosis by increasing cholesterol efflux from macrophages to extracellular high density lipoprotein [10], inhibiting vascular smooth muscle cells proliferation and migration [11], and suppressing pro-inflammatory cytokines [12,13]. Furthermore, it reduces NADPH oxidase expression, therefore diminishes oxidative stress [14] and increases endothelial nitric oxide production [10]. Additionally, 1,25(OH)2D suppresses markers of cardiac hypertrophy and regulates myocardial extracellular matrix turnover, thus protecting against cardiac fibrosis [15]. 1,25(OH)2D also suppresses the renin-angiotensin-aldosterone system [16]. Antidiabetic properties of vitamin D include increasing insulin secretion and sensitivity [17].

Vitamin D pathway incorporates several proteins. Two of these, megalin and cubulin, are receptors localized in the kidney proximal tubule that mediate the uptake of the filtered Vitamin D Binding protein (DBP) –25(OH)D complex through apical clathrin-coated pits into coated vesicles and subsequently to endosomes. There, the DBP-25(OH)D dissociates from the receptors due to acidifica-
was obtained by centrifugation of whole blood at 2500 rpm (Eppendorf Fixed-angle rotor F-34-6-38, 3500 g) for 10 min at 4 °C and was stored at –80 °C until 25(OH)D analysis.

Selection of the candidate genes

The candidate genes and polymorphisms were selected based on a prior knowledge of their involvement in the metabolic pathway of 25(OH)D in humans. SNPs were only included if they were validated and non-synonymous, indicating potential functionality, if they had a known minor allele frequency (MAF) > 0.1, or if they had a previously shown association with 25(OH)D levels. The selected SNPs were megalin (rs2075252 and rs4668123) and cubilin (rs1801222 and rs12766939).

Genotyping

Genomic DNA was extracted from whole blood samples using an ABIOutTM Genomic DNA Blood/Cell Culture Extraction Kit following the manufacturer’s instructions (Applied Bio Inc., Washington, USA). Absorbance at 260 nm was measured with the FLUOstar® Omega Nanodrop instrument (BMG Labtech, Ortenberg, Germany) and DNA concentration was calculated using the Nanodrop nucleic acid application module. DNA purity was assessed by 260/280 absorbance ratios. A ratio of ~1.8 is generally accepted as “pure” for DNA and 100 μg/mL was the minimum DNA concentration accepted. DNA extraction was repeated for samples that failed to meet the minimum DNA concentration and purity recommended for genotyping.

The polymorphisms rs2075252 and rs4668123 in the megalin gene and rs1801222 in the cubilin gene were genotyped using a polymerase chain reaction – restriction fragment length polymorphism (PCR-RFLP) method. The National Center for Biotechnology Information primer designing tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to design specific primers for the polymorphisms rs2075252, rs4668123, and rs1801222, which are listed in Table 2. The thermal profile of the polymerase chain reaction (PCR) of the three SNPs was initiated with a 5 min denaturation period at 95 °C, followed by 35 cycles of denaturation at 95 °C, annealing (temperatures in Table 1) and extension at 72 °C, with each step lasting 30 sec. The thermal profiles end with a final extension period of 10 min at 72 °C. Successful amplification was checked by electrophoresis. The PCR products were purified using a PureLink® PCR Purification Kit (Invitrogen, California, USA) following the manufacturer’s instructions. Restriction enzymes (New England Biolabs, Hitchin, UK) are summarized in Table 1. The reaction was conducted by combining 10 μL of PCR product for each SNP with 17 μL nuclelease-free water, 2 μL CutSmart Buffer and 1 μL of the restriction enzyme. Post restriction, the products were electrophoresed on a 2% agarose gel and viewed under ultraviolet gel documentation system. To confirm the accuracy of genotyping, a randomly selected sample (15%) of the study cohort was reanalyzed.

The genotyping for the rs12766939 SNP was performed in 96-well plates using the validated fluorogenic 5′-nucleotide genotyping TaqMan assay C_3135025_10 (which includes designed probes and primers as supplied by Applied Biosystems, Massachusetts, USA) using a Stratagene Mx3005P qPCR – Agilent Genomics real-time qPCR system. The assay was carried out according to the manufacturer’s instructions. Each reaction mix consisted of the following: 20 ng of genomic DNA diluted to 11.25 μL with DNase-free water, 13.75 μL of SNP reaction mixture consisting of 12.5 μL of TaqMan Universal PCR Mastermix and 1.25 μL of 20× working stock of SNP genotyping assay (probe and primer solution). The PCR program started with an initial denaturation at 95 °C for 10 min for activating the AmpliTaq Gold enzyme followed by 40 cycles of denaturation at 92 °C for 15 sec and an annealing/extension temperature at 62 °C for 1 min. Allelic discrimination assays were performed using two TaqMan MGB probes (VIC/FAM dye) that target the SNP sites. The obtained genotyping data were presented according to the NCBI SNP cluster reports. Positive control samples (homozygote for wild alleles, heterozygote, or homozygote for variant alleles) and the negative control sample were included in each batch of samples. Discordant samples were repeated.

Table 1

| Season of sample collection, N (%) | ACS patients | Control subjects |
|----------------------------------|-------------|-----------------|
| Fall                             |             |                 |
| Winter                           |             |                 |
| Summer                           |             |                 |
| Smokers/Non-Smokers, N (%)       |             |                 |
| Smokers                          |             |                 |
| Non-smokers                      |             |                 |
| Other chronic conditions         |             |                 |
| Diabetes, N(%)                   | 19 (10.27%) | 14 (10.53%)     |
| Hypertension, N(%)               | 13 (7.03%)  | 7 (5.26%)       |
| Age (years)                      | 54.75 ± 0.7 | 53.62 ± 0.78    |
| BMI (kg/m²)                      | 25.4 ± 0.33** | 24.6 ± 0.37    |
| Clinical Diagnosis               |             |                 |
| ST elevated MI, N (%)            | 134 (72.43%) | 101 (75.94%)    |
| Non-ST elevated MI, N (%)        | 31 (16.76%)  | 22 (16.54%)     |
| Unstable angina, N (%)           | 20 (10.81%)  | 10 (7.52%)      |
| N(%)                             | 185         | 143             |
| Overall, N = 185                 | Men, N = 133 | Women, N = 52  |
| Overall, N = 143                 | Men, N = 128 | Women, N = 15  |

**Number of smokers and non-smokers is also significantly different between patients and controls at P < 0.001 calculated by Chi-squared test.

***Number of smokers and nonsmokers is significantly different from the control group at P < 0.001 calculated by Mann-Whitney test.

25(OH)D determination

25(OH)D levels were measured using UPLC-MS/MS, which permitted an individualized assessment of both vitamin D metabolite forms: 25(OH)D$_3$ and 25(OH)D$_2$ [22,23]. Waters Acquity Xevo TQD
System instrument (Waters Corporation Milford, MA, USA) was used for detection which consists of an ACQUITY UPLC H-Class system and Xevo™ TQD triple-Quadrupole tandem mass spectrometer with an electrospray ionization (ESI) interface. An Acuity UPLC BEH C18 Phenyl Column (2.1 × 10 cm, particle size: 1.7 μm) was used to separate analytes (Waters Corporation Milford, MA, USA). According to agreed-upon standards, subjects were categorized as normal when their total 25(OH)D concentration were equal to or exceeded 30 ng/mL and less than 20 ng/mL, respectively of 25(OH)D2. The lower limit of quantification (LOQ) for these compounds was 5 ng/mL. The lower limit of detection (LOD) of either metabolite was 1.5 ng/mL. The recovery of 25(OH)D2 and 25(OH)D3 ranged from 86% to 98% over the analytical range of the assay.

**Statistical analyses**

Analyses were performed using Graphpad Prism statistics software, version 6.01 and SPSS 13.0. The D’Agostino and Pearson omnibus test was used to test for normality. Odds ratio (Chi-squared test) was used to measure the risk of susceptibility to ACS. The association of different genotypes of a SNP with 25(OH)D2 and 25(OH)D3 was assessed by performing multiple logistic regression analysis to eradicate the influence of age, gender, BMI and smoking on both the incidence of ACS and vitamin D status in addition. The Hardy-Weinberg equilibrium was calculated for each SNP by investigating the connection separately in patients, then in controls and finally by pooling all subjects together. The genotypes of megalin rs2075252 and rs4668123 polymorphism products of the malgenin rs2075252 and rs4668123 SNPs and cubilin rs1801222 SNPs are presented in Table 1.

| Rs          | Alleles | Primers for PCR amplification (5’-3’) | Annealing temperature (C) | PCR product length (bp) | RFLP analysis |
|-------------|---------|---------------------------------------|---------------------------|-------------------------|---------------|
| Meaglin polymorphisms |         |                                       |                           |                         |               |
| rs2075252   | C/T     | F: TGTTGTTTAAGCTAGCTTCC                 | 61.0                      | 352                     | Aanal         |
|             |         | R: AGAAAGAATCAGGAAAGCTTGG               |                           |                         |               |
| rs4668123   | C/T     | F: ACAATTGGGAATTTGGGGC                 | 61.0                      | 550                     | Fipl          |
|             |         | R: ATGACGACTCGGCTATCT                   |                           |                         |               |
| Cubilin polymorphisms |     | F: TGACCTACAGGTTCGATGGTGTG            | 57.0                      | 451                     | Blsi          |
| rs1801222   | G/A     | R: TGTGCCCTCGAGAATGTACC                |                           |                         |               |

Genotyping

Representative gels of PCR-restriction fragment length polymorphism products of the megalin rs2075252 and rs4668123 SNPs and the cubilin rs1801222 SNPs are presented in Fig. 1.

The genotypes distribution pattern of the megalin rs2075252 and rs4668123 SNPs and cubilin rs1801222 and rs12766939 SNPs were consistent with the Hardy Weinberg equilibrium (P > 0.05). Allelic and genotypic distributions of the four polymorphisms among patients and controls are presented in Table 4.

Genotype and allelic distributions of megalin rs2075252 were not different between patients and controls (P > 0.05) as shown in Table 4. Individuals with the megalin rs4668123 CC genotype have a 2.2 times higher risk of incidence of ACS when compared with individuals with either TT or CT genotypes (P = 0.0003). The C variant also represented a higher risk for ACS than did the T variant (P = 0.0005; OR = 1.863). After performing multiple logistic regression, the adjusted P value was 0.001, indicating that the megalin rs4668123 polymorphism may be a risk factor for ACS.

As for cubilin rs1801222 polymorphism, Chi-squared test revealed that individuals with the GG genotype have 1.7 times the risk of incidence of ACS than did individuals with the AA or GA genotypes. (P = 0.0442) Overall, 80.5% of the patients with ACS were high risk GG genotype carriers, while 18.4% were GA genotype carriers. Regarding controls 70.4% were GG, while 29.6% were GA genotype carriers. However, multiple logistic regression revealed that cubilin rs1801222 might not be an independent risk factor for ACS (adjusted P > 0.05).

Statistical analyses revealed the association of the cubilin rs12766939 with ACS incidence with the predominance of the G allele (P = 0.0337; OR = 1.4) and the predominance of G carrier genotypes (AG and GG) (P = 0.0182; OR = 1.8) in ACS patients. Similar to the cubilin rs1801222 SNP, multivariate logistic regression revealed that cubilin rs12766939 SNP might not be an independent risk factor for ACS (P > 0.05).

The association of each SNP with 25(OH)D levels was assessed by investigating the connection separately in patients, then in controls and finally by pooling all subjects together. The megalin rs4668123 influenced 25(OH)D2, 25(OH)D3 and total 25(OH)D concentrations, when pooling all subjects together, and the TT genotype exhibited the highest concentrations of serum vitamin D, followed by the CT genotype. The carriers of the CC genotype showed lower values of serum vitamin D and higher frequencies of vitamin D insufficiency and of vitamin D deficiency when compared to the other genotypes. After performing multivariate logistic regression, the adjusted P value was 0.007 for total 25(OH)D. By contrast, the megalin rs2075252 SNP was not associated with 25(OH)D2, 25(OH)D3 or total 25(OH)D levels in either the patient or the control groups in the genotypic model. Similarly, cubilin
rs1801222 and rs12766939 SNPs lacked 25(OH)D predictive abilities (Table 5).

The results are expressed as mean ± SEM. Vitamin D levels were compared between genotypes in each SNP using the non-parametric Kruskal-Wallis test. Adjusted P values for association of SNP genotypes and total 25(OH)D (ng/mL) were calculated using multiple logistic regression analysis.

**Discussion**

Coronary Artery Diseases, which include ACS, are complex multifactorial polygenic disorders that are thought to result from interactions between a person’s genetic makeup and various environmental factors [28]. This case control study investigated associations of serum 25(OH)D concentrations and functionally relevant genetic variants in megalin and cubilin genes, that encode for the two kidney receptors, in the vitamin D metabolic pathway, with ACS risk in Egyptians.

**Table 3**

| 25(OH)D levels in the study groups: patients with ACS and healthy controls. |
|---------------------------------|---------------|---------------|
|                                | ACS patients  | Control subjects |
|                                | Overall, N = 185 | Men, N = 133 | Women, N = 52 | Overall, N = 143 | Men, N = 128 | Women, N = 15 |
| Serum 25(OH)D (ng/mL)           |                |               |
| 25(OH)D ≥30 ng/mL, N (%)        | 17.37 ± 0.42  | 17.76 ± 0.52  | 16.42 ± 0.67  | 43.48 ± 1.06  | 43.43 ± 1.15  | 42.41 ± 2.68  |
| 25(OH)D 20–30 ng/mL, N (%)      | 10 (5.4%)     | 9 (6.8%)      | 1 (1.9%)      | 126 (88.1%)   | 112 (87.5%)   | 14 (93.3%)    |
| 25(OH)D <20 ng/mL, N (%)        | 23 (12.4%)    | 18 (13.5%)    | 5 (9.6%)      | 12 (8.3%)     | 11 (8.5%)     | 1 (6.7%)      |

Comparison of Vitamin D status among patients and controls

|                                | Overall Patients with ACS, N = 185 | Overall Controls, N = 143 | Odds Ratio (95% CI) | P value      |
|                                | Insufficient and Deficient 25(OH)D <30 ng/mL, N (%) | 175 (94.6%) | 17 (11.89%) | Insufficient and Deficient Vs. Sufficient 25(OH)D > 30 ng/mL, N (%) | 10 (5.4%) | 126 (88.1%) | 129.7 (57.5–292.8) | <0.0001**** |

The serum 25(OH)D results are expressed as mean ± SEM. P value was calculated by Chi-squared test.

**Fig. 1.** Representative 2% agarose gel electrophoresis of restriction digestion products. (A) Megalin rs2075252 polymorphism. Lane 1, a 100-bp ladder; lanes 2, 3 and 5, are a CT heterozygote with 139 bp, 213 bp and 352 bp fragments; lanes 4, 7 and 8 are a CC homozygote with 139 bp and 213 bp fragments; and lane 6 is a TT homozygote with a single 352 bp fragment. (B) Megalin rs4668123 polymorphism. Lane 1, a 100-bp ladder; lanes 2, 4, 5 and 7 are a CT heterozygote with 245 bp, 305 bp and 550 bp fragments; lanes 3, 6 and 8 are a CC homozygote with 245 bp and 305 bp fragments; and lane 9 is a TT homozygote with a single 550 bp fragment. (C) Cubilin rs1801222 polymorphism. Lane 1, a 100-bp ladder; lane 3 is a GA heterozygote with 153 bp, 298 bp and 451 bp fragments; lanes 2, 4, 5, 6 and 7 are a GG homozygote with 153 bp and 298 bp fragments; and lane 8 is a AA homozygote with a single 451 bp fragment.
Comparison between the distribution pattern of megalin and cubilin polymorphism genotypes and the serum 25(OH)D3, 25(OH)D2 and total 25(OH)D concentrations in all study subjects.

Table 4

| Genotype | 25(OH)D3 (ng/mL) | 25(OH)D2 (ng/mL) | Total 25(OH)D (ng/mL) |
|----------|------------------|------------------|-----------------------|
| Megalin rs2075252 (E4049K) | | | |
| CC (%) | 133 (71.9%) | 100 (69.9%) | 100 (69.9%) |
| CT (%) | 45 (24.3%) | 40 (28%) | 40 (28%) |
| TT (%) | 7 (3.8%) | 3 (2.13%) | 3 (2.13%) |
| C (%) | 311 (84%) | 240 (83.9%) | 240 (83.9%) |
| T (%) | 59 (16%) | 46 (16.1%) | 46 (16.1%) |

| Megalin rs4668123 (T2872A) | | | |
| CC (%) | 117 (63.2%) | 62 (43.4%) | 62 (43.4%) |
| CT (%) | 59 (31.9%) | 68 (47.6%) | 68 (47.6%) |
| TT (%) | 9 (4.9%) | 13 (9.1%) | 13 (9.1%) |
| C (%) | 293 (79.2%) | 192 (57.1%) | 192 (57.1%) |
| T (%) | 77 (20.8%) | 94 (32.9%) | 94 (32.9%) |

| Cubilin rs1801222 (S253F) | | | |
| GG (%) | 149 (80.54%) | 81 (70.43%) | 81 (70.43%) |
| GA (%) | 34 (18.38%) | 34 (29.57%) | 34 (29.57%) |
| AA (%) | 2 (1.08%) | 0 (0%) | 0 (0%) |
| G (%) | 332 (89.7%) | 196 (85.2%) | 196 (85.2%) |
| A (%) | 38 (10.3%) | 34 (14.8%) | 34 (14.8%) |

| Cubilin rs12766939 | | | |
| AA (%) | 55 (29.9%) | 51 (44%) | 51 (44%) |
| AG (%) | 92 (50%) | 46 (39.75%) | 46 (39.75%) |
| GG (%) | 37 (20.1%) | 19 (16.4%) | 19 (16.4%) |
| A (%) | 38 (10.3%) | 34 (14.8%) | 34 (14.8%) |
| G (%) | 332 (89.7%) | 196 (85.2%) | 196 (85.2%) |

| P-value of odds ratio was calculated by Chi-squared Fisher’s exact test to compare the allele frequencies and genotypic differences between ACS and control groups. Multiple logistic regression was done to test the association of each individual studied SNP and the incidence of ACS. Megalin rs2075252, Megalin rs4668123, Cubilin rs1801222 and Cubilin rs12766939 to eliminate the confounders: age, sex, smoking and BMI (r = 0.766, 0.756, 0.754 and 0.754 for Megalin rs2075252, Megalin rs4668123, Cubilin rs1801222 and Cubilin rs12766939 respectively). The adjusted P-value was calculated using multivariate multiple logistic regression. |

Table 5

P-value of odds ratio was calculated using multivariate multiple logistic regression.

| SNP ID | Genotype | P-value | 25(OH)D3 (ng/mL) | 25(OH)D2 (ng/mL) | Total 25(OH)D (ng/mL) |
|--------|----------|---------|------------------|------------------|-----------------------|
| Megalin E4049K (rs2075252) | CC | 0.6595 | 7.63 ± 0.49 | 0.205 | 28.86 ± 1.06 | 0.6746 | 0.487 |
| | CT | 2.226 ± 1.35 | 7.46 ± 0.63 | 29.71 ± 1.79 | 26.94 ± 5.94 |
| | TT | 22.19 ± 5.43 | 4.76 ± 1.28 | | |
| Megalin T2872A (rs4668123) | CC | ***0.0021 | 6.7 ± 0.49 | **0.0128 | 26 ± 1.12 | ***0.0018 | ***0.007 |
| | CT | 22.14 ± 1.15 | 8.24 ± 0.6 | 32.38 ± 1.48 | 34.59 ± 4.32 |
| | TT | 25.34 ± 3.28 | 9.26 ± 2.13 | | |
| Cubilin S253F (rs1801222) | GG | 0.4215 | 6.47 ± 0.38 | 0.0449 | 26.62 ± 1 | 0.2032 | 0.980 |
| | GA | 22.37 ± 1.57 | 8.76 ± 1.02 | 30.97 ± 2.1 | |
| | AA | 13.66 ± 8.17 | 3.5 ± 2.12 | 17.16 ± 10.29 | |
| Cubilin rs12766939 | AA | 0.7261 | 8.29 ± 0.75 | 0.162 | 29.85 ± 1.7 | 0.6532 | 0.315 |
| | AG | 20.12 ± 1 | 6.51 ± 0.51 | 26.63 ± 1.26 | |
| | GG | 21.56 ± 1.24 | 6.44 ± 0.57 | 27.75 ± 2.04 | |

The prevalence of cardiovascular diseases, such as ischemic heart disease, heart attack, stroke, heart failure, cardiac arrhythmia, and hypertension, and mortality from these disorders are significantly higher in patients with low vitamin D levels than in patients with adequate levels [2,26,30–33]. The prevalence of cardiovascular risk factors, such as hypertriglyceridemia, hypercholesterolemia, diabetes, inflammatory markers, and high body mass index, was also increased [26]. The cardiovascular risk also increased across the categories of 25(OH)D deficiency, so that subjects with levels 10 to <15 ng/mL had a 53% higher risk, and in those with the levels <10 ng/mL an 80% higher risk [31]. A study that monitored 18,225 men for 10 years showed that low levels of 25(OH)D were associated with a high risk of myocardial infarction [30,34].

Till now, there are no studies on Egyptians that have examined the association of vitamin D deficiency on the risk of ACS. However, there are some that studied the association of vitamin D deficiency on other disorders such as Non Alcoholic Fatty Liver Disease (NAFLD) [35] and rheumatoid arthritis [36]. Both studies portrayed results similar to those displayed in the current study. Vitamin D levels in patients with NAFLD were 18.76 ± 14.37 ng/mL and were 40.36 ± 22.24 ng/mL in the study’s controls. Results also showed that low Vitamin D levels were frequent in rheumatoid arthritis patients (22 ± 9.2 ng/mL) compared to the controls (26 ± 9.6 ng/mL).

Although several studies investigated several genetic determinants of vitamin D and their non-skeletal outcomes, studies investigating the relationship of polymorphisms in the vitamin D pathway and ACS are limited. The focus of the present study was the triangular relationship between the two megalin genetic vari-
The allele distribution of SNP rs4668123 was similar to that in type distribution in German controls was 53% CC, 37% CT and 10% that rs2075252 SNP genotype distribution in German controls were different from Asian subjects [38]. Another study reported the association of TT genotypes of the megalin rs4668123 SNP was considered an independent ACS risk factor. Compared with the homozygous TT genotype and lowest in the CC genotype, and intermediate in CT genotype. Multiple logistic regression revealed that megalin rs4668123 genotype represents an independent determinant for total 25(OH)D. Taken together, these results suggest that the non-synonymous megalin rs4668123 SNP could potentially alter the functionality of the encoded megalin protein to affect the reabsorption of 25(OH)D-DBP complex from the proximal tubular lumen. The result would be a phenotype that has altered serum levels of 25(OH)D3, 25(OH)D2 and total 25(OH)D. Therefore, genotypic variants also might have an association with circulating vitamin D levels. Smoking also might had an impact over, genotypic variants also might have an association with survival rates after developing ACS. Other factors that might have influenced the vitamin D status such as usage of sunscreen, vitamin D supplementation and alcohol consumption are lacking. Smoking also might had an impact on vitamin D levels [45]. These might be considered the study’s limitations. No ECG data were available for control subjects. There was also no data on lipid profiles of the subjects available. Moreover, genotypic variants also might have an association with survival rates after developing ACS, however, the study was cross sectional and survival rates after developing ACS weren’t tracked.

**Conclusions**

The results of the present study indicate that megalin rs4668123 SNP genotype CC, cubilin rs1801222 SNP genotype GC and cubilin rs12766939 SNP genotype GG are associated with a higher ACS incidence and can be considered risk factors, according to Chi-squared test. Conversely, the megalin rs2075252 SNP was not associated with increased ACS incidence. However, after performing multiple logistic regression analysis, only the megalin rs4668123 SNP was considered an independent ACS risk factor. Furthermore, the megalin rs4668123 CC genotype was associated with lower 25(OH)D levels. Replication of these findings in different populations, including populations of other racial and ethnic groups, will be of interest for confirming the biological significance of these polymorphisms in relation to vitamin D levels and the incidence of ACS.

**Compliance with Ethics Requirements**

The project was evaluated by the Ethics Committee of the German University in Cairo with regard participation of human patients or animals and/or clinical samples obtained from humans or animals, and with the respect of anonymity guaranteed to patients from whom any samples are being obtained.
Declaration of Competing Interest

The authors have declared no conflict of interest.

Acknowledgements

This work was supported by a grant from the Science and Technology Development Fund in Egypt (STDF 15041). We are grateful for the continuous support from the National Health Institute. The manuscript was revised by an editing service, SCRIBENDI, CANADA.

References

[1] Bikle Daniel D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014;21(3):319–29.
[2] Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266–81.
[3] Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004;79(3):362–71.
[4] DeLuca HF. History of the discovery of vitamin D and its active metabolites. BoneKey Rep 2014;3.
[5] Nair R, Mazeah A. Vitamin D: the sunshine vitamin. J Pharmacol Pharmacotherapeutics 2012;3(2):118–26.
[6] Arabi A, El Rassi R, El-Haj Fuleihan G. Hypovitaminosis D in developing countries:ndash;prevalence, risk factors and outcomes. Nat Rev Endocrinol 2010;6(10):550–61.
[7] Aljeefri N, Ahmed F. Prevalence of cardiovascular disease and associated risk factors among adult population in the gulf region: a systematic review. Adv Public Health 2015;2015:23.
[8] Wng ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014;11(5):276–89.
[9] Overbaugh KJ. Acute coronary syndrome. Am J Nurs 2009;109(5):42–52. quiz 15(1626–9, 17.
[10] Pilz S, Verheyen N, Grubler MR, Tomaschitz A, Wditz M, Brn B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168(4):503–11.
[11] Metamal ML, Mishos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168(4):503–11.
[12] Dobbins H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D levels and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168(12):1340–9.
[13] Almheiri I, Quyumi AA. Vitamin D and cardiovascular disease: controversy unresolved. J Am Coll Cardiol 2017;70(1):89–100.
[14] Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330(15):1041–6.
[15] Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res 2014;114(2):379–93.
[16] Wranicz J, Zostak-Wegierek D. Health outcomes of vitamin D. Part II. Role in cardiovascular disease prevention. Rozh Panstw Zakl Hig 2014;65(4):273–9.
[17] Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117(4):503–11.
[18] Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117(4):503–11.
[19] Almheiri I, Quyumi AA. Vitamin D and cardiovascular disease: controversy unresolved. J Am Coll Cardiol 2017;70(1):89–100.
[20] Almheiri I, Quyumi AA. Vitamin D and cardiovascular disease: controversy unresolved. J Am Coll Cardiol 2017;70(1):89–100.
[21] Almheiri I, Quyumi AA. Vitamin D and cardiovascular disease: controversy unresolved. J Am Coll Cardiol 2017;70(1):89–100.